{"entity":{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","aka":["Auckland Regional Cancer and Blood Service","Te Whatu Ora Auckland","University of Auckland Centre for Cancer Research"],"tldr":"New Zealand's largest hospital and cancer service, working with the University of Auckland's Auckland Cancer Society Research Centre, which developed hypoxia-activated and DNA-targeting anticancer drugs.","summary":"Auckland City Hospital in Grafton is New Zealand's largest public hospital and hosts the country's biggest cancer and blood service, providing medical, radiation and surgical oncology, haematology and stem cell transplant for the upper North Island, along with the national phase 1 trials unit and paediatric oncology at Starship Children's Hospital. Its academic partner, the University of Auckland's Auckland Cancer Society Research Centre, has a long record in cancer drug discovery, including the hypoxia-activated prodrugs tirapazamine analogues and tarloxotinib, the topoisomerase poison amsacrine, DNA-intercalating agents, and kinase inhibitors licensed to industry, and the university's Centre for Cancer Research coordinates New Zealand's translational and Māori health equity oncology research.","asOf":"2026-09-09","links":[{"label":"Te Whatu Ora Auckland","url":"https://www.adhb.health.nz"}],"tags":[],"related":["cancer-health-disparities"],"cancers":["colorectal","melanoma","aml","nsclc"],"sections":["drug-discovery","chemotherapy"],"technologies":["kinase-inhibitors","topoisomerase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dale-bramley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Auckland","country":"NZ","lat":-36.86,"lng":174.77,"institutionType":"hospital","website":"https://www.adhb.health.nz","university":"University of Auckland","programs":["Regional cancer and blood service","Auckland Cancer Society Research Centre drug discovery","Phase 1 trials","Paediatric oncology (Starship)"]},"route":"/institutions/auckland-city-hospital/","neighbours":{"term":[{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"person":[{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/"}]}}